WEARABLE HEALTH SOLUTIONS, INC. - Quarter Report: 2022 March (Form 10-Q)

Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

Mark One

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to _______

COMMISSION FILE NO. 000-56368

WEARABLE HEALTH SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Nevada	26-3534190	3669
(State or Other Jurisdiction of	IRS Employer	Primary Standard Industrial
Incorporation or Organization)	Identification Number	Classification Code
		Number

2901 W. Coast Highway, Suite 200, Newport Beach, CA 92663

(Address of principal executive offices)

Phone: (949) 270-7460

(Registrant’s telephone number)

Indicate by checkmark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

☐	Large accelerated filer	☐	Accelerated filer
☒	Non-accelerated filer	☒	Smaller reporting company
		☐	Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Applicable Only to Issuer Involved in Bankruptcy Proceedings During the Preceding Five Years.

N/A

Applicable Only to Corporate Registrants

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

Class		Outstanding as of May 5, 2022
Common Stock, $0.0001		1,493,142,608

WEARABLE HEALTH SOLUTIONS, INC.

TABLE OF CONTENTS

FOR THE THREE AND NINE MONTHS ENDED MARCH 31, 2022

PART I

Item 1.	Financial Statements	1

	Balance Sheets as of March 31, 2022 (unaudited) and June 30, 2021	1
	Statements of Operations for the Three and Nine Months Ended March 31, 2022 and 2021 (Unaudited)	2
	Statements of Changes in Shareholders’ Deficit for the Nine Months Ended March 31, 2022 and 2021 (Unaudited)	3
	Statements of Cash Flows for the Nine Months Ended March 31, 2022 and 2021 (Unaudited)	6
	Notes to the Financial Statements (Unaudited)	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	23

Item 4.	Controls and Procedures	24

PART II

Item 1.	Legal Proceedings	25

Item 1A.	Risk Factors	25

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	25

Item 3.	Defaults Upon Senior Securities	26

Item 4.	Mining Safety Disclosures	26

Item 5.	Other Information	26

Item 6.	Exhibits	27

	Signatures	28

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

Wearable Healthcare Solutions, Inc.

Consolidated Balance Sheets


	March 31, 2022			June 30, 2021
		(unaudited)
ASSETS
Current Assets
Cash and cash equivalents	$	569,973		$	847,430
Accounts receivable, net		–			25,694
Accounts receivable, other		2,000			2,000
Prepaid Inventory		16,197			22,682
Prepaid expenses		–			10,000
Total Current Assets		588,170			907,806

Property, Plant & Equipment
Dealer portal (net of $5,849 and $0 depreciation, as of March 31, 2022 and June 30, 2021, respectively)		44,151			–
Total Property, Plant & Equipment		44,151			–

Total Assets	$	632,321		$	907,806

LIABILITIES and SHAREHOLDERS' DEFICIT

COMMITMENTS AND CONTINGENCIES (Note 12)		–			–

Current liabilities
Accounts payable	$	107,268		$	331,876
Accrued expenses and other current liabilities		377,360			296,920
Accrued expenses - related party		320,101			579,673
Contract liabilities - Deferred revenue		82,306			108,298
Line of credit		397,500			397,500
Derivative liability		–			281,845
Notes payable		430,380			853,244
Note payable - other		50,000			50,000
Note payable - related party		47,000			425,000
Convertible notes - Leonite		–			260,000
Convertible notes- other		673,750			673,750
Total current liabilities		2,485,665			4,258,106
TOTAL LIABILITIES		2,485,665			4,258,106

SHAREHOLDERS’ DEFICIT
Preferred stock: 25,000,000 Shares Authorized, par value $0.0001
Series A Convertible Preferred Stock: $0.0001 par value; 100,000 shares authorized, 688 shares issued and outstanding as of March 31, 2022 and June 30, 2021, respectively.		1			1
Series B Convertible Preferred Stock: $0.0001 par value; 62,500 shares authorized, 9,938 shares issued and outstanding as of March 31, 2022 and June 30, 2021, respectively.		1			1
Series C Preferred Stock: $0.0001 par value; 6,944,445 authorized,6,838,889 and 138,886 shares issued and outstanding as of March 31, 2022 and June 30, 2021, respectively		684			684
Series D Preferred Stock: $0.0001 par value; 500,000 shares authorized, 425,000 shares issued and outstanding as of March 31, 2022 and June 30, 2021, respectively.		43			43
Series E Preferred Stock $0.0001 par value, 4,000,000 shares authorized, 4,000,000 and 1,900,000 shares issued and outstanding as of March 31, 2022 and June 30, 2021, respectively		400			190
Series E Preferred Stock to be issued (-0- and 100,000 shares as of March 31, 2022 and June 30, 2021, respectively)		–			57,000
Common stock
Common Stock: $0.0001 par value; 3,000,000,000 shares authorized,1,080,492,608 and 647,074,177 shares issued and outstanding as of March 31, 2022 and June 30, 2021, respectively		108,049			64,708
Common stock to be issued (407,632,500 and 20,050,000 shares as of March 31, 2022 and June 30, 2021, respectively)		6,535,559			169,005
Additional paid in capital		29,967,450			22,732,295
Accumulated deficit		(38,465,530	)		(26,374,227	)
Total Shareholders’ Deficit		(1,853,344	)		(3,350,300	)
Total Liabilities and Shareholders’ Deficit	$	632,321		$	907,806

The footnotes are an integral part of these unaudited financial statements

Wearable Healthcare Solutions, Inc.

Consolidated Statements of Operations

For the three and nine months ended March 31, 2022 and 2021 (unaudited)


	For the Three Months Ended						For the Nine Months Ended
	March 31, 2022			March 31, 2021			March 31, 2022			March 31, 2021
Revenue
Hardware revenue	$	5,659		$	90,412		$	82,644		$	296,426
Service revenue		207,323			192,909			736,957			739,345
Gross Revenue		212,982			283,321			819,601			1,035,771
Cost of sales		(111,434	)		(75,194	)		(457,307	)		(620,215	)
Gross profit		101,548			208,127			362,294			415,556

Operating expenses
Selling expense		44,346			32,552			318,708			34,650
Depreciation		2,500			–			5,849			–
Research and development expense		209,800			–			374,484			–
Consulting and professional fees		106,624			50,554			462,998			158,513
Insurance		28,124			13,515			50,507			35,272
Rent		4,050			3,300			12,555			11,418
Salaries and wages		6,974,610			280,809			10,904,649			2,532,293
Software expense		24,500			10,512			22,887			13,506
General and administrative		89,084			24,835			295,659			89,998
Total Operating expenses		7,483,638			416,077			12,448,296			2,875,650

Loss from operations		(7,382,090	)		(207,950	)		(12,086,002	)		(2,460,094	)

Other income / (expense)
Other income		23,000			–			23,000			–
Gain on debt extinguishment		–			–			96,145			–
Gain on loan forgiveness		–			222,981			–			81,000
Change in fair value of derivative instrument		–			–			(213,053	)		(31,940	)
Gain on settlement of accounts payable		–			–			156,616			–
Interest expense		(8,493	)		(28,069	)		(68,009	)		(121,001	)
Total other income (expense)		14,507			194,912			(5,301	)		(71,941	)

Net loss before taxes		(7,367,583	)		(13,038	)		(12,091,303	)		(2,532,035	)
Income tax		–			–			–			–
Net loss	$	(7,367,583	)	$	(13,038	)	$	(12,091,303	)	$	(2,532,035	)

Net loss per common share - Basic and Diluted	$	(0.0073	)	$	(0.00	)	$	(0.01487	)	$	(0.00366	)

Weighted average common shares outstanding - Basic & Diluted		1,008,459,767			557,529,809			813,299,239			692,481,701

The footnotes are an integral part of these unaudited financial statements

Wearable Healthcare Solutions, Inc.

Consolidated Statement of Shareholders’ Deficit

For the three and nine months ended March 31, 2022 and 2021 (unaudited)


	Series A			Series B			Series C			Series C to be issued
	Shares		Amount	Shares		Amount	Shares		Amount	Shares			Amount

As at June 30, 2020	688	$	1	9,938	$	1	138,886	$	14	6,700,003		$	375,200

Loss for the period	–		–	–		–	–		–	–			–
Issuance of Series C Preferred shares							6,700,003		670	(6,700,003	)		(375,200	)
Return of preferred stock
Preferred stock issued/officer comp
Common stock issued/officer comp

As at September 30, 2020	688	$	1	9,938		1	6,838,889	$	684	–		$	–

Loss for the period	–		–	–		–	–		–	–			–
3a10 shares
Common stock for officer comp
Preferred stock issued/officer comp
Common stock issued/officer comp

As at December 31, 2020	688	$	1	9,938		1	6,838,889	$	684	–		$	–

Loss for the period	–		–	–		–	–		–	–			–
3a10 shares
Common stock for officer comp
Preferred stock issued/officer comp
Common stock issued/officer comp

As at March 31, 2021	688	$	1	9,938		1	6,838,889	$	684	–		$	–

As at June 30, 2021	688	$	1	9,938		1	6,838,889	$	684	–	$	–

Loss for the period	–		–	–		–	–		–	–		–
Common stock for comp
Common stock for debt conversion
Common stock for officer comp
Preferred stock for compensation
Issuance of issuable shares

As at September 30, 2021	688	$	1	9,938	$	1	6,838,889	$	684	–	$	–

Loss for the period	–		–	–		–	–		–	–		–
Common stock for services
Common stock for comp
Common stock for debt conversion
Preferred stock for compensation
Subscriptions receivable
Issuance of issuable shares

As at December 31, 2021	688	$	1	9,938	$	1	6,838,889	$	684	–	$	–

Loss for the period	–		–	–		–	–		–	–		–
Common stock for services
Common stock for comp
Common stock for debt conversion
Preferred stock for compensation
Subscriptions receivable
Issuance of issuable shares

As at March 31, 2022	688	$	1	9,938	$	1	6,838,889	$	684	–	$	–

Wearable Healthcare Solutions, Inc.

Consolidated Statement of Shareholders’ Deficit

For the three and nine months ended March 31, 2022 and 2021 (unaudited)

(continued)


	Series D			Series E					Series E to be issued
	Shares		Amount	Shares			Amount		Shares		Amount

As at June 30, 2020	425,000	$	43	4,000,000		$	400		1,000,000	$	650,000

Loss for the period	–		–	–			–		–		–
Issuance of Series C Preferred shares
Return of preferred stock				(4,000,000	)		(400	)
Preferred stock issued/officer comp				1,000,000			100				(80,000	)
Common stock issued/officer comp

As at September 30, 2020	425,000	$	43	1,000,000		$	100		1,000,000	$	570,000

Loss for the period	–		–	–			–		–		–
3a10 shares
Common stock for officer comp
Preferred stock issued/officer comp
Common stock issued/officer comp

As at December 31, 2020	425,000	$	43	1,000,000		$	100		1,000,000	$	570,000

Loss for the period	–		–	–			–		–		–
3a10 shares
Common stock for officer comp
Preferred stock issued/officer comp
Common stock issued/officer comp

As at March 31, 2021	425,000	$	43	1,000,000		$	100		1,000,000	$	570,000

As at June 30, 2021	425,000	$	43	1,900,000	$	190	100,000		$	57,000

Loss for the period	–		–	–		–	–			–
Common stock for comp
Common stock for debt conversion
Common stock for officer comp
Preferred stock for compensation				2,000,000		200
Issuance of issuable shares

As at September 30, 2021	425,000	$	43	3,900,000	$	390	100,000		$	57,000

Loss for the period	–		–	–		–	–			–
Common stock for services
Common stock for comp
Common stock for debt conversion
Preferred stock for compensation				100,000		10	(100,000	)		(57,000	)
Subscriptions receivable
Issuance of issuable shares

As at December 31, 2021	425,000	$	43	4,000,000	$	400	0		$	–

Loss for the period	–		–	–		–	–			–
Common stock for services
Common stock for comp
Common stock for debt conversion
Preferred stock for compensation
Subscriptions receivable
Issuance of issuable shares

As at March 31, 2022	425,000	$	43	4,000,000	$	400	0		$	–

Wearable Healthcare Solutions, Inc.

Consolidated Statement of Shareholders’ Deficit

For the three and nine months ended March 31, 2022 and 2021 (unaudited)

(continued)


	Common Stock			Common Stock to be issued				Additional Paid in Capital		Accumulated					Total
	Shares		Amount	Shares		Amount		Amount		Deficit			Total

As at June 30, 2020	297,399,177	$	29,740	10,350,000	$	71,415	$	18,578,122	$	(23,061,221	)	$	(3,356,285	)

Loss for the period	–		–	–		–		–		(1,949,592	)		(1,949,592	)	–
Issuance of Series C Preferred shares								374,530					–
Return of preferred stock													(400	)
Preferred stock issued/officer comp								649,900					570,000
Common stock issued/officer comp	200,000,000		20,000	150,000		1,500		1,120,000					1,141,500

As at September 30, 2020	497,399,177	$	49,740	10,500,000	$	72,915	$	20,722,552	$	(25,010,813	)	$	(3,594,777	)	–

Loss for the period	–		–	–		–		–		(569,405	)		(569,405	)	–
3a10 shares	48,989,000		4,899										4,899
Common stock for officer comp				225,000		1,376							1,376
Preferred stock issued/officer comp				150,000		985							985
Common stock issued/officer comp													–

As at December 31, 2020	546,388,177	$	54,639	10,875,000	$	75,276	$	20,722,552	$	(25,580,218	)	$	(4,156,922	)	–

Loss for the period	–		–	–		–		–		(13,038	)		(13,038	)	–
3a10 shares	11,500,000		1,150					113,850					115,000
Common stock for officer comp				225,000		3,218							3,218
Preferred stock issued/officer comp													0
Common stock issued/officer comp													–

As at March 31, 2021	557,888,177	$	55,789	11,100,000	$	78,494	$	20,836,402	$	(25,593,256	)	$	(4,051,743	)

As at June 30, 2021	647,074,177	$	64,708	20,050,000		$	169,005		$	22,732,295		$	(26,374,227	)	$	(3,350,300	)	(3,350,300)

Loss for the period	–		–	–			–			–			(4,354,735	)		(4,354,735	)	–
Common stock for comp	7,000,000		700	5,000,000			60,000			74,300						135,000
Common stock for debt conversion	25,269,253		2,527							250,166						252,693
Common stock for officer comp				225,000			2,498									2,498
Preferred stock for compensation										2,999,800						3,000,000
Issuance of issuable shares	232,500,000		23250	(10,000,000	)		(100,000	)		2,301,750						2,225,000

As at September 30, 2021	911,843,430	$	91,185	15,275,000		$	131,503		$	28,358,311		$	(30,728,962	)	$	(2,089,845	)

Loss for the period	–		–	–			–			–			(368,985	)		(368,985	)	–
Common stock for services	10,000,000		1,000	(10,000,000	)		(69,000	)		68,000						–
Common stock for comp				225,000			2,422									2,422
Common stock for debt conversion	41,149,178		4,114							420,900						425,014
Preferred stock for compensation										56,990						–
Subscriptions receivable										(100,000	)					(100,000	)
Issuance of issuable shares	97,500,000		9750	20,000,000			200,000			965,250						1,175,000

As at December 31, 2021	1,060,492,608	$	106,049	25,500,000		$	264,925		$	29,769,450		$	(31,097,947	)	$	(956,394	)

Loss for the period	–		–	–			–			–			(7,367,583	)		(7,367,583	)	–
Common stock for services																–
Common stock for comp				402,132,500			6,470,634									6,470,634
Common stock for debt conversion																–
Preferred stock for compensation																–
Subscriptions receivable																–
Issuance of issuable shares	20,000,000		2,000	(20,000,000	)		(200,000	)		198,000						–

As at March 31, 2022	1,080,492,608	$	108,049	407,632,500		$	6,535,559		$	29,967,450		$	(38,465,530	)	$	(1,853,343	)	(1,853,344)

The footnotes are an integral part of these unaudited financial statements

Wearable Healthcare Solutions, Inc.

Consolidated Statement of Cash Flows

For the nine months ended March 31, 2022 and 2021 (unaudited)


	2022			2021
Cash flow from operating activities
Net loss	$	(12,091,303	)	$	(2,532,035	)
Adjustment for non-cash charges and other items:
Depreciation and amortization		5,849			–
Common stock issued for services		–			4,899
Stock compensation expense		9,610,554			1,829,150
Loss on change in fair value of derivative		213,053			31,940
Gain on accounts payable extinguishment		(156,616	)		–
Gain on settlement of convertible notes payable		(96,145	)		–
Amortization of debt discount		–			4,167
Total adjustments		(2,514,608	)		(661,879	)
Changes in working capital
Decrease / (increase) in accounts receivable		25,694			11,746
Decrease / (increase) in prepaid inventory		–			59,898
Decrease / (increase) in prepaid expenses		16,485			–
(Decrease) / increase in trade and other payables		(67,992	)		(53,402	)
(Decrease) / increase in accrued expenses		99,393			264,536
(Decrease) / increase in accrued expenses - related party		(204,121	)
(Decrease) / increase in deferred revenue		(25,992	)		(63,790	)
Total changes in working capital		(156,533	)		218,988
Cash flow used in operating activities		(2,671,141	)		(442,891	)

Cash flow provided by investing activities
Decrease / (increase) in property, plant & equipment		(50,000	)		–
Acquisition of company		–			(400	)
Cash flow provided by financing activities		(50,000	)		(400	)

Cash flow provided by financing activities
Proceeds from note payable		25,000			550,000
Proceeds from issuance of stock for cash		3,300,000			–
Repayments of note payable		(825,864	)		(80,166	)
Payments to related parties		(55,452	)		(14,968	)
Cash flow from financing activities		2,443,684			454,866
Increase in cash and cash equivalents		(277,457	)		11,575
Cash and cash equivalents at the beginning of the period		847,430			–
Cash and cash equivalents at end of the period	$	569,973		$	11,575

NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversions of notes and accrued interest	$	269,954		$	–

Cash paid for interest and taxes
Interest	$	–		$	–
Taxes	$	–		$	–

The footnotes are an integral part of these unaudited financial statements.

WEARABLE HEALTHCARE SOLUTIONS INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2022 and June 30, 2021 (unaudited)

Note 1 – Nature and Continuance of Operations

Wearable Health Solutions Inc. (the Company) was incorporated as Medical Alarm Concepts Holding, Inc., on June 4, 2008, under the laws of the State of Nevada. The Company was formed for the sole purpose of acquiring all of the membership units of Medical Alarm Concepts LLC, a Pennsylvania limited liability company (“Medical LLC”). On May 26, 2016, the Company filed an Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada to change its name from “Medical Alarm Concepts, Inc.” to “Wearable Health Solutions Inc.”

Wearable Health Solutions provides mobile health (mHealth) products and services to be used by customers in case of an emergency. As a provider of personal emergency response devices, we provide innovative wearable healthcare products, tracking services, and turn-key solutions that enable our users to be proactive with their health, as well as safe and protected.

Our flagship products are the iHelp devices, the 3G and the next generation iHelp MAX™ - personal emergency alarms that are used to summon help in the event of an emergency at home.

Basis of presentation

The accompanying interim condensed consolidated financial statements are unaudited, but in the opinion of management of Wearable Health Solutions, Inc. (the Company), contain all adjustments, which include normal recurring adjustments, necessary to present fairly the financial position at March 31, 2022 and the results of operations and cash flows for the three and nine months ended March 31, 2022. The balance sheet as of June 30, 2021, is derived from the Company’s audited financial statements.

Certain information and footnote disclosures normally included in financial statements that have been prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission, although management of the Company believes that the disclosures contained in these financial statements are adequate to make the information presented therein not misleading. For further information, refer to the financial statements and the notes thereto included in the Company’s Annual Report on the Form 10 for the fiscal year ended June 30, 2021, that was filed with the Securities and Exchange Commission on November 19, 2021, with its final amendment on March 23, 2022.

The results of operations for the three and nine months ended March 31, 2022, are not necessarily indicative of the results of operations to be expected for the full fiscal year ending June 30, 2022.

Note 2 – Summary of Significant Accounting Policies

Principles of Consolidation – The consolidated financial statements include the accounts of the Company and its wholly-owned or controlled operating subsidiaries: Medical Alarm Concepts, LLC and Boapin. All intercompany accounts and transactions have been eliminated.

Use of Estimates – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates. Such estimates include valuation of stock compensation, valuation of derivative liabilities, allowance for doubtful accounts.

Cash and Cash Equivalents – For purposes of the Statement of Cash Flows, the Company considers highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

Accounts Receivable – We estimate credit loss reserves for accounts receivable on an individual receivable basis. A specific impairment allowance reserve is established based on expected future cash flows and the financial condition of the debtor. We charge off customer balances in part or in full when it is more likely than not that we will not collect that amount of the balance due. We consider any balance unpaid after the contract payment period to be past due. There are $-0- and $25,694 in accounts receivables net of allowances of $23,705 and $23,705 at March 31, 2022 and June 30, 2021, respectively.

Software Development for internal use - The Company accounts for software development costs in accordance with applicable guidelines. Software development costs include payroll, employee benefits, stock-based compensation expense, and other headcount-related expenses associated with product development. Software development costs also include third-party development and programming costs, localization costs incurred to translate software for international markets, and the amortization of purchased software code and services content. Such costs related to software development are included in software development expense until the point that technological feasibility is reached. Once technological feasibility is reached, such costs are capitalized and depreciated over the useful estimated lives of the software. For software modifications or developments, the Company expenses the costs. The Company purchased its dealer portal for $50,000 on August 30, 2021, to be depreciated over 5 years.

Concentration of Credit Risk - Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company currently maintains cash balances in excess of FDIC insurance maximums. The Company performs ongoing credit evaluations of its customers and maintains allowances for potential credit losses.

Recognition of Revenues – In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 establishes a single comprehensive model for entities to use in accounting for revenue arising from outside contracts with customers and supersedes most of the existing revenue recognition guidance and notes that lease contracts with customers are a scope exception. ASU 2014-09 requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. On August 12, 2015, the FASB issued ASU 2015-14 to defer the effective date of ASU 2014-09. Public business entities may elect to adopt the amendments as of the original effective date; however, adoption is required for annual reporting periods beginning after December 15, 2017. The Company adopted this pronouncement July 1, 2018.

The Company’s revenues are derived principally from utilizing new technology in the medical alarm industry to provide 24-hour personal response monitoring services and related products to subscribers with medical- or age-related conditions. The Company recognizes revenue for services over time as the performance obligations are met and for product sales at a point in time when the performance obligations are met. For hardware sales, the Company recognizes revenues when the product is shipped. Customers are billed on Net 30 terms. For service revenue, the Company recognizes revenues when the service is provided. For customers who pay several months at a time, the Company records revenues for the month’s services and the balance of funds to deferred revenues and records the balance of revenues as they become current.

Schedule of revenues
	3 months ended March 31,				9 months ended March 31,
REVENUES	2022		2021		2022		2021
Hardware revenue	$	5,659	$	90,412	$	82,644	$	296,426
Service revenue		207,323		192,909		736,957		739,345
TOTAL REVENUES	$	212,982	$	283,321	$	819,601	$	1,035,771

The following table discloses changes in contract liabilities for the three and nine months ended March 31, 2022.

Schedule of unearned revenue
	3 months ended March 31, 2022			9 months ended March 31, 2022
Balance at beginning of period – December 31, 2021 and June 30, 2021	$	95,015		$	108,298
Contract liabilities		48,510			168,823
Recognition of contract liabilities		(61,219	)		(194,815	)
Balance at the end of the period - March 31, 2022	$	82,306		$	82,306

Contract liabilities at March 31, 2022 and June 30, 2021 was $82,306 and $108,298, respectively. The deferred revenue represents quarterly and annual prepaid service fees, which were invoiced and paid at the onset of customer service agreements and which pertain to service obligations not realized at March 31, 2022 and June 30, 2021, respectively. We have no agreements longer than 12 months.

Deferred Taxes – The Company accounts for income taxes under Section 740-10-30 of the FASB Accounting Standards Codification. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements of operations in the period that includes the enactment date.

ASC 740, Income Taxes, requires a company to first determine whether it is more likely than not (which is defined as a likelihood of more than fifty percent) that a tax position will be sustained based on its technical merits as of the reporting date, assuming that taxing authorities will examine the position and have full knowledge of all relevant information. A tax position that meets this more-likely-than-not threshold is then measured and recognized at the largest amount of benefit that is greater than fifty percent likely to be realized upon effective settlement with a taxing authority.

The Federal and state income tax returns of the Company for 2021, 2020, and 2019 are subject to examination by the Internal Revenue Service and state taxing authorities for three (3) years from the date filed.

Fair value of financial instruments. The Company measures its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB Accounting Standards Codification No. 820, Fair Value Measurement (“ASC 820”), which provides guidance with respect to valuation techniques to be utilized in the determination of fair value of assets and liabilities. Approaches include, (i) the market approach (comparable market prices), (ii) the income approach (present value of future income or cash flow), and (iii) the cost approach (cost to replace the service capacity of an asset or replacement cost). ASC 820 utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

Level 3: Unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable.

From time to time, our financial instruments include cash, accounts payable and accrued expenses, convertible notes, lines of credit, and credit cards.

Research and Development - Research and development costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are also expensed as incurred, due to the uncertainty with respect to future cash flows resulting from the patents. For the three and nine months ended March 31, 2022 and 2021, the Company recorded $43,472 and $149,000 and $-0- and $-0- in research and development costs, respectively.

Basic and Diluted Loss per Common Share - Basic loss per common share excludes dilution and is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted loss per share gives effect to all potential dilutive common shares outstanding during the period of compensation. Diluted income (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that would then share in the net income of the Company, subject to anti-dilution limitations.

Schedule of anti-dilutive shares
	Basis of conversion	Dilution	March 31, 2022	June 30, 2021
Series A Convertible	688 shares outstanding	1 share A: 2 shares	1,376	1,376
Series B Convertible	9,938 shares outstanding	1 share B: 2 shares	19,876	19,876
Series C Convertible	6,838,889 and 138,886 shares outstanding as of March 31, 2022 and June 30, 2021, respectively	1 share C: 10 shares	68,388,890	1,388,860
Series C Convertible	-0- and 6,700,003 shares to be issued as of March 31, 2022 and June 30, 2021, respectively	1 share C: 10 shares	–	67,000,030
Series D Convertible	425,000 shares outstanding	1 share D: 100 shares	42,500,000	42,500,000
Series E Convertible	4,000,000 and 1,900,000 shares outstanding as of March 31, 2022 and June 30, 2021, respectively	1 share E: 100 shares	400,000,000	190,000,000
Series E Convertible Shares to be issued	-0- and 100,000 Series E shares to be issued as of March 31, 2022 and June 30, 2021, respectively	1 share E: 100 shares	–	10,000,000
			510,910,142	300,910,142

Because the Company incurred losses for the past two years, the basic and diluted share bases will be presented as the same. For the three and nine months ended March 31, 2022 and 2021, the Company incurred losses of ($0.01) and ($0.00) per basic share and diluted share, respectively.

Recent Accounting Pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the current accounting for leases and while retaining two distinct types of leases, finance and operating, (1) requires lessees to record a right of use asset and a related liability for the rights and obligations associated with a lease, regardless of lease classification, and recognize lease expense in a manner similar to current accounting, (2) eliminates most real estate specific lease provisions, and (3) aligns many of the underlying lessor model principles with those in the new revenue standard. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. For public companies, the new standard is effective for annual and interim periods in fiscal years beginning after December 15, 2018. For all other entities, including emerging growth companies, this standard is effective for annual reporting periods beginning after December 15, 2019, and interim periods within fiscal years beginning after December 2020. Earlier application is permitted. The Company evaluated the impact on the financial statements and implemented the provisions of ASU 2016-02 for the annual financial statements for the year ended June 30, 2019.

In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, as part of its initiative to reduce complexity in accounting standards. The amendments in the ASU are effective for fiscal years beginning after December 15, 2020, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating the effect, if any, that the ASU will have on its consolidated financial statements.

The Company reviewed all recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the AICPA and the SEC, and they did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Note 3 – Going Concern

The accompanying consolidated financial statements for the three and nine months ended March 31, 2022 and 2021 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As at March 31, 2022 and June 30, 2021, the Company has shown losses for the last 2 years and has an accumulated deficit of ($38,465,530) and ($26,374,227), respectively. Management believes that the Company’s capital requirements will depend on many factors including the success of the Company’s development efforts and its efforts to raise capital. Management also believes the Company needs to raise additional capital for working capital purposes. There can be no assurance that the Company will be able to obtain the additional capital resources necessary to implement its business plan or that any assumptions relating to its business plan will prove accurate.

These factors raise substantial doubt about our ability to continue as a going concern for a period of 12 months from the issue date of this report. The consolidated financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 4 – Inventory, Prepaid Inventory, and Prepaid Expenses

The Company maintains some inventories in house and purchases some of its inventory overseas. Inventories, except for stock in transit, are stated at lower of cost and net realizable value. Stock in transit is valued at cost comprising invoice value plus other charges thereon. Net realizable value is the estimated selling price in ordinary course of business less estimated costs of completion and selling expenses. The quantity of inventory may vary from time to time depending on the delivery schedule of overseas shipments.

As of March 31, 2022 and June 30, 2021, the Company had $-0- and $-0- in inventory in-house, respectively, as well as $16,197 and $22,682 in prepaid inventories in transit, respectively.

The Company recorded prepaid public relations and investor relations (PR/IR) services of $-0- and $10,000 in March 31, 2022 and June 30, 2021, respectively.

As of March 31, 2022 and June 30, 2021, the Company had $-0- and $10,000 in prepaid expenses, respectively.

Note 5 – Property, Plant, and Equipment

The Company has $20,000 in furnishings, $19,689 in office computers and equipment, and capitalized software development costs of $45,900 which are fully depreciated. On August 30, 2021, the Company purchased its dealer portal for $50,000 for internal use, amortized over 60 months.

As of March 31, 2022 and June 30, 2021, the Company recorded $44,151 and $-0- in net Property, Plant, and Equipment, respectively:


	March 31, 2022			June 30, 2021
Furniture	$	20,000		$	20,000
Office computers, equipment, software		19,689			19,689
Software development costs		45,900			45,900
Dealer Portal		50,000			–
Property, plant, and equipment		135,589			85,589
Less accumulated depreciation – portal		(5,849	)		–
Less accumulated depreciation		(85,589	)		(85,589	)
Net property, plant, and equipment	$	44,151		$	-0-

Note 6 – Accounts payable and accrued expenses and liabilities

The Company recorded Accounts Payable of $107,268 and $331,876, directly related to operating costs, as of March 31, 2022 and June 30, 2021, respectively.

Accrued expenses are expenses that have been incurred but not yet paid, mainly include legal fees, audit fees and other professional fees as well as interests accrued in connection with notes payable and credit line. The Company recorded $377,360 and $296,920 in accrued expenses and other current liabilities as of March 31, 2022 and June 30, 2021, respectively.

3a10 filing

On August 17, 2020, the Wearable Health Solutions, Inc., (the “Company”) entered into a settlement agreement and stipulation (“Settlement Agreement”) with Trillium Partners LP (“Trillium”) in connection with the settlement of $310,494.38 of bona fide obligations the Company owed to certain of its creditors. The Settlement Agreement was subject to a fairness hearing, and on September 15, 2020, a Federal court in the District of Maryland held a fairness hearing and granted approval of the Settlement Agreement. If the Settlement Agreement is satisfied in full, the Company shall reduce the Company’s debt obligations equal to $310,494.38 in exchange for the issuance of settlement shares of Company’s common stock pursuant to the terms of section 3(a)(10) of the Securities Act of 1933, in multiple tranches, at a price that is sixty percent to the lowest closing bid price for the common stock for the delivery of such tranche. At no time may Trillium beneficially own more than 9.99% of the Company’s outstanding common stock.

In October 2020, the Company issued 48,989,000 shares of WHSI common stock, to be valued at 60% of the lowest bid price for the common stock on the date of the stock issuance. Subsequently, in April 2021, the agreement was voided for non-participation, and all 48,989,000 shares were returned to treasury.

Note 7 – Notes Payable and Note payable-other

Short term bridge loan - COHEN

On July 31, 2020, the Company secured a $500,000 short term bridge loan from an unaffiliated individual (“COHEN”), 12% interest, due and payable October 20, 2020. The loan is currently in default and continues to accrue interest at 12%.

At June 30, 2021, the Company recorded short term note payable of $500,000, expensed $55,027 in interest and accrued the same in interest liability for the year ended June 30, 2021.

On August 19, 2021, the Company repaid $300,000 of principal. In November 2021, the Company repaid an additional $100,000 in principal.

At March 31, 2022, the Company recorded short term note payable of $100,000, expensed $18,649 in interest and accrued the same in interest liability for the nine months ended March 31, 2022.

Note payable – stock purchases under Reg A

In March 2021 and June 2021, the Company accepted loans of $115,000 from two unaffiliated investors, pending blue sky registrations in two states. In July 2021, the Company accepted loans of $20,000 from two unaffiliated investors, pending blue sky registrations in two additional states. The notes bear interest at 5% and the full amount of the note plus interest is convertible at the Reg A fixed price of $0.01, when possible.

In October 2021, the Company accepted a loan of $5,000 from one unaffiliated investor, pending blue sky registration in his state. As of March 31, 2022 and June 30, 2021, the Company recorded $140,000 and $115,000 in notes payable for stock purchases under Reg A, accrued and expensed interest of $8,736 and $1,594, respectively.

As of March 31, 2022 and June 30, 2021, the Company has outstanding $430,380 and $853,244 in notes payable, respectively.

Note Payable – Other

In November 2016, the Company secured a $50,000 loan from a party related to a previous CEO, bearing 4% interest, the loan maturing after a successful money raise of $1,000,000 through the acquisition of convertible notes payable (See BENZA, D2CF). The $1,000,000 fundraising was never completed, and the Company has been accruing interest on the original principal amount at 4% since inception. On July 22, 2021, the Company filed suit for damages and the party filed a countersuit on August 26, 2021. There has been no resolution to this situation, and we continue to accrue interest at the face amount.

As of March 31, 2022 and June 30, 2021, the Company expensed $1,500 and $2,000 in interest fees and has accrued $10,983 and $9,283 in interest payable, respectively.

Convertible note payable – other

On March 1, 2016 and March 3, 2016, the Company closed a private placement and received an aggregate of $612,500 by issuing $660,000 (“BENZA”) and $13,750 (“B2CF”) unsecured convertible notes (“convertible notes”) and warrants to two investors, net of original issue discount of $61,250 per the subscription agreements. All outstanding warrants have expired.

As of March 31, 2022 and June 30, 2021, the Company reported $673,750 and $673,750 in convertible notes payable, respectively.

On July 22, 2021, the Company filed suit for damages resulting from the related party. On November 4, 2021, Benza Pharma LLC filed a countersuit. To date, there has been no resolution or settlement. The loans are recognized on the financials with no discount.

Convertible Note: Leonite Capital, LLC:

On November 19, 2019, the Company, together with Hypersoft Ventures (collectively, the “Borrower”), received $135,000 on issuing the first tranche of $150,000 (prorated original issue discount of $15,000) of a $250,000 unsecured convertible note (“Leonite Convertible Note”) from Leonite Capital, LLC, a Delaware limited liability company (“Leonite”), net of an aggregate original issue discount of up to $77,778. The Leonite Convertible Note bears annual interest at the Prime Rate plus eight percent (8%), not to exceed twelve percent (12%) per annum, computed on a 365/360 basis, and is due nine months from the date of issuance. The Leonite Convertible Note is convertible into shares of the Company’s common stock at a conversion price equal to $0.02 per share with anti-dilution features. In connection with its purchase of the Leonite Convertible Note, the Company issued to Leonite 2,700,000 shares of common stock, prorated for the initial tranche. On June 4, 2021, the Company and Leonite amended the convertible note to $260,000 which included interest and penalties and extended the due date to June 4, 2023.

The Company has determined that the conversion feature embedded in the Leonite Convertible Note constitutes a derivative and has been bifurcated from the Leonite Convertible Note and recorded as a derivative liability, with a corresponding discount recorded to the associated debt, on the accompanying balance sheet, and revalued to fair market value at each reporting period. The initial issuance yielded a derivative liability of $94,225, with a discount of $150,000 to be amortized over the 9-month life of the Leonite Convertible Note.

Significant assumptions used in calculating fair value of conversion feature of Leonite Convertible Note at issuance date are as follows:


Expected Dividends	Expected volatility	Risk-free rate of interest	Expected term (year)	Exercise (Conversion) price	Common stock price per share
0.00%	809.71%	0.0154%	0.75	$0.02	$0.01300

On June 4, 2021, the Company and Leonite renegotiated the convertible note for two years, face value of $260,000. At June 30, 2021, the Company recorded $281,845 in derivative liabilities.

On July 29, 2021, Leonite converted $42,750 in debt plus $2,250 in fees to 15,000,000 shares, and on August 27, 2021, Leonite converted $44,475 and $2,250 in fees to 10,269,253 shares.

On October 6, 2021, Leonite converted $57,952 in debt and interest plus $2,250 in fees to 13,231,209 shares, and on October 26, 2021, Leonite converted the remaining balance of $125,000 in debt and interest, and $2,250 in fees, to 27,917,969 shares, collectively resulting in a $96,145 gain on debt extinguishment.

Schedule of extinguishment of debt
Balance at June 30, 2021	$	260,000
Accrued interest		9,954
Leonite Convertible Note converted		(269,954	)
Total		0
Less: debt discount		(0	)
Balance at March 31, 2022	$	0

The resulting derivative valuation is calculated as follows:


Derivative as of June 30, 2021	$	281,845
Change in fair value		238,155
		520,000
Write off due to conversions		(176,800	)
Derivative value as of September 30, 2021	$	343,200
Change in fair value		(25,102	)
		318,098
Write off due to conversion		(221,953	)
		96,145
Gain on extinguishment		(96,145	)
Derivative as of March 31, 2022	$	–

Significant assumptions used in calculating fair value of conversion feature of Leonite Convertible Note as of March 31, 2022 are as follows:


Expected Dividends	Expected Volatility	Risk-free rate of interest	Expected term (year)	Exercise (Conversion) price	Common stock price per share
0.00%	269.75%	0.0007%	1.9288	$0.00550	$0.01

As of March 31, 2022 and June 30, 2021, the Company has recorded $-0- and $260,000 in Convertible Note: Leonite, respectively.

Credit line – MediPendant New York Inc.

On September 30, 2014, our subsidiary entered into a line of credit with Medi Pendant New York, Inc. (“MNY”), which is partially owned by a principal of its subsidiary. Under the line of credit agreement, the Company will be able to borrow up to $500,000 with the rate of interest of 6.5% per annum. The maturity date of the credit line is September 30, 2017, with a one-year extension to September 30, 2018. On January 31, 2015, the limit on the line of credit was increased to $500,000 with same interest rate and due date. The Company issued 200,000 shares of common stock to one of the owners of MNY as consideration for the increase of line of credit. These shares were issued on October 19, 2015 and value at $28,000 which was the fair market value at the grant date. The line of credit is currently in default.

As of March 31, 2022 and June 30, 2021, the Company has recorded $397,500 and $397,500 in outstanding line of credit balance, respectively.

Note 10 – Stockholders’ Deficit

Capital Stock:

The Company is currently authorized to issue 3,000,000,000 shares of common stock, par value of $0.0001 per share, and 25,000,000 shares of preferred stock, par value of $0.0001.

For the nine months ended March 31, 2021, the Company issued 200,000,000 shares to its officers as compensation, valued at $1,140,000 or $.0057 per share, accrued 150,000 shares as a bonus, valued at $1,500 or $.01 per share, and accrued 525,000 shares as officer compensation, valued at $3,861. All shares were recorded at the stock price of the date of agreement or grant

For the nine months ended March 31, 2022, the Company issued 7,000,000 common shares to employees and contractors for contractual bonuses, valued at $75,000 or $.0107 per share, accrued 5,000,000 shares in bonuses to be paid, valued at $60,000 or $.0105 per share, issued 66,418,431 for $260,000 in debt, $9,954 in interest, and $9,000 in fees, valued at $677,707, which represents the fair value of shares issued, accrued 450,000 to be issued for management compensation, valued at $4,920 an average of $.0109 per share, and sold 340,000,000 shares under the Reg A at $3,400,000 or $.01 per share, 10,000,000 of which were accrued to be issued as of December 31, 2021. In January 2022, the Company issued 20,000,000 shares previously accrued and recorded 402,132,500 shares to be issued in employee compensation and bonuses, valued at $6,470,634. All shares were recorded at the quoted stock price of the date of agreement or grant.

As of March 31, 2022 and June 30, 2021, the Company has 1,080,492,608 and 697,074,199 shares of common stock issued and outstanding and 407,632,500 and 20,050,000 issuable common stock shares, respectively.

Offering pursuant to Regulation A

On September 11, 2020, the Company filed a 1-A offering statement with the Securities and Exchange commission, offering up to 500,000,000 shares of common stock at $.01 to raise up to $5,000,000. The offering was amended on October 14, 2020 and can be viewed on the SEC website, www.sec.gov.

Preferred Stock.

Series A Convertible Preferred Stock: The Company is currently authorized to issue 100,000 shares of Series A Convertible Preferred Stock, par value $0.0001, convertible at 1 share of Series A preferred stock for 2 shares of common stock. These shares have no voting rights.

Series B Convertible Preferred Stock: The Company is currently authorized to issue 62,500 shares of Series B Convertible Preferred Stock, par value $0.0001, convertible at 1 share of Series B preferred stock for 2 shares of common stock. These shares have voting rights and vote on an “as converted” basis in actions required to have Series B Preferred Stockholder approval.

Series C Convertible Preferred Stock: The Company is currently authorized to issue 6,944,445 shares of Series C Convertible Preferred Stock, par value $0.0001, convertible at 1 share of Series C Convertible Preferred Stock for 10 shares common stock. These shares have voting rights and vote on an “as converted” basis in actions required to have Series C Preferred Stockholder approvals.

Series D Convertible Preferred Stock: The Company is currently authorized to issue, 500,000 shares of Series D Convertible Preferred Stock, par value $0.0001, convertible at 1 share of Series D Convertible Preferred stock for 100 shares of common stock, as amended. These shares have voting rights and vote on an “as converted” basis in actions required to have Series D Preferred Stockholder approval.

Series E Convertible Preferred Stock: The Company is currently authorized to issue 4,000,000 shares of Series E Convertible Preferred Stock, par value $0.0001, convertible at 1 share of Series E Convertible Preferred Stock for 100 shares of common stock. In addition, Series E Convertible Preferred Stock carry voting rights of 10,000 votes per share of Series E Convertible Preferred Stock.

During the nine months ended March 31, 2021, the Company issued 6,700,003 shares of Series C Convertible Preferred Stock, valued at $375,000 or $.056 per shares in conjunction with the purchase of the Boapin portal (See Note 11), returned 4,000,000 shares of Series E Convertible Preferred Stock, valued at $400 or $.0001, and issued 1,900,000 shares of Series E Convertible Preferred shares to two officers for services, valued at $1,223,000 an average of $.64 per share. All shares were recorded at the stock price of the date of agreement or grant on an as-converted basis.

During the nine months ended March 31, 2022, the Company issued 1,000,000 shares of Series E Convertible Preferred shares to each of its two directors for services, valued at $3,000,000 or $1.50 per share, and issued 50,000 shares to each of its two directors, previously accrued, valued at $57,000 or $.57 per share. All shares were recorded at the quoted common stock price of the date of agreement or grant on an as-converted basis.

As of March 31, 2022 and June 30, 2021, the Company had 688 shares of Series A Convertible Preferred Stock, 9,938 shares of Series B Convertible Preferred Stock, 6,838,889 shares of Series C Convertible Preferred Stock, 425,000 shares of Series D Convertible Preferred Stock, and 4,000,000 shares of Series E Convertible Preferred Stock issued and outstanding, respectively.

All shares were valued at the stock price on the day of transaction or conversion.

Note 11 – Related Party Transactions

Note payable – BOAPIN purchase

In June 2019, the Company purchased the BOAPIN portal, including all software, licensing, and ownership rights from Hypersoft Ventures, Inc., a related party, for $425,670, which includes six million seven hundred thousand (6,700,003) shares of Series C Convertible Preferred stock and a note for $425,000, bearing twelve percent (12%) interest with no prepayment or delinquency clauses.

On October 28, 2021, the Company repaid $105,000 in principal, and on December 1, 2021, the Company repaid $150,000 in principal.

During the quarter ended March 31, 2022, Company repaid $123,000 in principal, accrued $1,410 in interest, and expensed the same.

As of March 31, 2022 and June 30, 2021, the Company has recorded Note payable-BOAPIN of $47,000 and $425,000, and accrued interest of $44,315 and $28,225, respectively.

Accrued expenses and due to related party

From time to time, related parties loaned the company working capital for day-to-day operations, respectively. These are short-term loans which bear no interest, and the Company expects to repay these loans within the coming year. In addition, salary accruals owed to the officers of the Company have been included in the Due to related party line item.

As of March 31, 2022 and June 30, 2021, the Company owes $320,101 and $579,673 in related party payables, respectively.

Note 12 – Commitments and contingencies

Commitments and Contingencies. The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.

If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not believe, based upon information available at this time that these matters will have a material adverse effect on the Company’s financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows.

The Company is currently involved in the below litigation matters. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

Wearable Health Solutions, In. v. Barry Honig, GRQ Consultants Inc., Benza Pharma LLC and John Does 1-10, Supreme Court of the State of New York County of New York, July 22, 2021. Company is disputing the validity of Notes from 3/2016 and seeking damages, reparations, and related costs.

	2)	GRQ Consultants, Inc. v. Wearable Health Solutions, Inc., Supreme Court of the State of New York, County of New York, August 26, 2021, Parties are seeking summary judgment of $50,000 plus accrued interest in response to lawsuit by Company regarding $50,000 loan from 11/2016.

	3)	Benza Pharma LLC, Sandor Capital, LP, and John Lemak v. Wearable Health Solutions, Inc., District Court, Clark County, Nevada, Parties are seeking summary judgment of $3,000,000 plus accrued interest in regards to convertible notes payable from March, 2016.

	4)	Medical Alarm Concepts LLC v. MCA Cure, LLC, Superior Court of New Jersey, Law Division, Morris County. Company is seeking return of payments for non-performance plus attorney fees and court costs. A settlement was reached between the parties whereby MCA Cure will pay an initial $10,000 and $6,500 each month until debt is satisfied in 2023 (See Note 14).

Note 13 – Office lease

The Company maintains its corporate offices in Newport Beach, California, on a month-to-month basis. The subsidiary maintains a warehouse office in Pennsylvania to facilitate inventory arrival and product shipment. The 3-year lease at $1,100 per month expired on September 30, 2021. The lease has been renewed for 12 months at $1,300 per month beginning October 1, 2021. Expenditures for the nine months ending March 31, 2022 and 2021 are as follows:

Schedule lease cost
		2022		2021
Rent expense	$	12,555	$	11,418

Note 14 – Other income - settlement

Settlement

In 2019, the Company engaged MCA Cure to negotiate settlements with two note holders, and paid MCA Cure a total of $97,625. In 2020, the Company discovered MCA Cure had not performed when bank accounts were levied for $33,705 and $18,705, being subsequently refunded, and engaged an attorney to recover funds. Currently the Company has a settlement agreement in place with Susquehanna Salt Loan and has hired an attorney to recover funds and damages from MCA Cure. In February 2022, a settlement was reached with MCA Cure for fees and attorney costs of $105,125, amortized at 1.5%, by which the Company would receive an initial payment of $10,000, and $6,500 monthly until the debt is satisfied in May, 2023, with stipulations for any potential default.

As of March 31, 2022 and 2021, the Company has recorded $23,000 and $-0- to other revenue, respectively.

Note 15 – Subsequent Events

Management is reporting the passing of its founder Ronald Adams. The company has shared the news corporately with its network of 200 domestic and international dealers and vendors. Mr. Adams responsibilities have been assumed by Marc Cayle as Vice President of Innovation and Development for the company. Mr. Cayle has over 18 years of experience in the Seniors Health Care and Personal Emergency Response Systems (PERS) sectors. He also founded several Seniors Care related companies specific to the Home Health Care industry.

The company has updated its websites at; wearablehealthsolutions.com; ihelpalarm.com; 1800medalert.com and wearablehealthsolutions.com/investor-relations reflecting corporate, product, DTC and investor relations references.

Common stock

In April 2022, the Company issued 402,650,000 shares of common stock to its management for compensation and bonuses, previously accrued, 10,000,000 shares of restricted common stock to an independent consultant, and cancelled 28,000,000 shares. As of the date of this filing, the Company has 1,465,143,608 shares issued and outstanding.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements. For this purpose, any statements contained in this Report that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking information includes statements relating to future actions, prospective products, future performance or results of current or anticipated products, sales and marketing efforts, costs and expenses, interest rates, outcome of contingencies, financial condition, results of operations, liquidity, business strategies, cost savings, objectives of management, and other matters. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “will,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “continue” and similar expressions or the negative of these similar terms. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking information to encourage companies to provide prospective information about themselves without fear of litigation so long as that information is identified as forward-looking and is accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those projected in the information.

These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that we cannot predict. In evaluating these forward-looking statements, you should consider various factors, including the following: (a) those risks and uncertainties related to general economic conditions, (b) whether we are able to manage our planned growth efficiently and operate profitable operations, (c) whether we are able to generate sufficient revenues or obtain financing to sustain and grow our operations, (d) whether we are able to successfully fulfill our primary requirements for cash, which are explained below under “Liquidity and Capital Resources”. We assume no obligation to update forward-looking statements, except as otherwise required under the applicable federal securities laws. Unless stated otherwise, terms such as the “Company,” “Wearable Health,” “we,” “us,” “our,” and similar terms shall refer to Wearable Health Solutions, Inc., a Nevada corporation, and its subsidiaries.

Company Overview

Wearable Health Solutions Inc. (the Company) was incorporated as Medical Alarm Concepts Holding, Inc. on June 4, 2008, under the laws of the State of Nevada. The Company was formed for the sole purpose of acquiring all of the membership units of Medical Alarm Concepts LLC, a Pennsylvania limited liability company (“Medical LLC”). On May 26, 2016, the Company filed an Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada to change its name from “Medical Alarm Concepts, Inc.” to “Wearable Health Solutions Inc.”

Our flagship products are the iHelp devices, the 3G and the next generation iHelp MAX™ - personal emergency alarms that are used to summon help in the event of an emergency at home.

Results of Operations

Results for the Three Months Ended March 31, 2022, compared to the Three Months Ended March 31, 2021

Working Capital	March 31, 2022 $			March 31, 2021 $
Cash		569,973			847,430
Current Assets		588,170			907,806
Current Liabilities		2,485,665			4,258,106
Working Capital (Deficit)		(1,897,495	)		(3,350,300	)

Operating Revenues

The Company had revenues of $212,898 and $283,321 for the three months ended March 31, 2022 and 2021, respectively.

Cost of Revenues

The Company’s cost of revenues for the three months ended March 31, 2022 and 2021 was $111,434 and $75,194, respectively. Cost of revenues increased for the three months ended March 31, 2022 due to purchasing in smaller quantities at higher prices in 2022 coupled with product unavailability and delayed shipments due to the pandemic.

Gross Profit

The Company’s gross profit for the three months ended March 31, 2022 was $101,548, compared to $208,127 at March 31, 2021. The decrease in the Company’s gross profit was due to decreased hardware sales and increased cost of goods, for the reasons described above.

Operating Expenses

Operating expenses consisted of salaries and wages, research and development, consulting and professional fees, and additional operating costs. For the three months ended March 31, 2022, operating expenses were $7,483,638 compared to $416,077 for the three months ended March 31, 2021. The primary expenses for the three months ended March 31, 2022, were salaries and wages of $6,974,610, which was mostly made up of shares issued to our Officers and Directors; the primary expenses for the three months ended March 31, 2021, were salaries and wages and professional services totaling $280,809.

Other Income (Expense)

The Company had other income for the three months ended March 31, 2022 and 2021 of $14,507 and $194,912, respectively. Other income consisted of $23,000 in payments for settlement of the MCA Cure complaint and interest expense of $8,493 in 2022, as compared with gain on loan forgiveness of $222,981 and interest expense of $28,069 in 2021.

Net loss

The net loss for the three months ended March 31, 2022, was $7,367,538 as compared to $13,038 for the three months ended March 31, 2021.

Results for the Nine Months Ended March 31, 2022, compared to the Nine Months Ended March 31, 2021

Operating Revenues

The Company had revenues of $819,601 and $1,035,771 for the nine months ended March 31, 2022 and 2021, respectively.

Cost of Revenues

The Company’s cost of revenues for the nine months ended March 31, 2022 and 2021, was $457,307 and $620,215, respectively.

Cost of revenues decreased for the nine months ended March 31, 2022 as compared to March 31, 2021, was due to fewer hardware purchases in 2022 coupled with product unavailability and delayed shipments due to the pandemic.

Gross Profit

The Company’s gross profit for the nine months ended March 31, 2022 and 2021, was $362,294, and $415,556, respectively. The decrease in the Company’s gross profit was due to the decrease in hardware sales and decrease in hardware purchases in 2022, as described above.

Operating Expenses

Operating expenses consisted of salaries and wages, research and development, consulting and professional fees, and additional operating costs. For the nine months ended March 31, 2022, operating expenses were $12,352,152 compared to $2,875,650 for the nine months ended March 31, 2021. The primary expenses for 2022 were salaries and wages of $10,904,649, which was mostly made up of shares issued to our Officers and Directors; the primary expenses for 2021 were salaries and wages totaling $2,532,293.

Other Income (Expense)

The Company had other income for the nine months ended March 31, 2022 and 2021 of $5,301 and $71,941, respectively. Other income (expense) consisted of $23,000 income in payments for settlement of the MCA Cure complaint, $213,053 expense in change in fair value of derivative instrument, gain of $516,617 in settlement of accounts payable, gain of $96,145 in extinguishment of debt, and interest expense of $68,009 as of March 31, 2022, as compared to gain on loan forgiveness of $81,000, $31,940 expense in change in fair value of derivative instrument, and interest expense of $121,001 as of March 31, 2021, respectively.

Net loss

The net loss for the nine months ended March 31, 2022, was $12,091,303 as compared to $2,532,035 for the period ended March 31, 2021.

Liquidity and Capital Resources

The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan. Since its inception, the Company has been funded by related parties through capital investment, borrowing of funds and through the sale of equity.

At March 31, 2022, the Company had total current assets of $588,170, as compared to $907,806, at June 30, 2021. Current assets consisted primarily of cash and prepaid expenses. At March 31, 2022, the Company had total current liabilities of $2,485,664 compared to $4,258,106, at June 30, 2021. Current liabilities consisted primarily of accounts payable, accrued liabilities and accrued compensation, notes payable and convertible notes payable.

We had negative working capital of $1,897,494, as of March 31, 2022, as compared to $3,350,300, as of June 30, 2021.

Cash flow from Operating Activities

During the nine months ended March 31, 2022, cash used in operating activities was $(2,671,141) compared to $(442,891) for the same period ended March 31, 2021. The increase in the amounts of cash used in operating activities was due to the increase in operations, issuance of shares for services and personnel.

Cash flow from Financing Activities

For the nine months ended March 31, 2022, cash provided by financing activities was $2,443,685 compared to $454,65 provided during the nine months ended March 31, 2021. The increase in the amounts of cash flow from financing activities was due to the sale of common stock under the Reg A filing.

Quarterly Developments

None.

Subsequent Developments

Management is saddened to report the passing of its founder Ronald Adams. The company has shared the news corporately with its network of 200 domestic and international dealers and vendors. Mr. Adams responsibilities have been assumed by Marc Cayle as Vice President of Innovation and Development for the company. Mr. Cayle has over 18 years of experience in the Seniors Health Care and Personal Emergency Response Systems (PERS) sectors. He also founded several Seniors Care related companies specific to the Home Health Care industry.

In addition, the company has updated its websites at; wearablehealthsolutions.com; ihelpalarm.com; 1800medalert.com and wearablehealthsolutions.com/investor-relations reflecting corporate, product, DTC and investor relations references.

Going Concern

The accompanying unaudited interim consolidated condensed financial statements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of the Company on a going-concern basis. The going concern basis assumes that assets are realized, and liabilities are extinguished in the ordinary course of business at amounts disclosed in the consolidated financial statements. The Company has incurred recurring losses from operations and has an accumulated deficit of $38,465,530. The Company’s ability to continue as a going concern depends upon its ability to obtain adequate funding to support its operations through continuing investments of debt and/or equity by qualified investors/creditors, internally generated working capital and monetization of intellectual property assets. These factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management is currently pursuing a business strategy which includes raising the necessary funds to finance the Company’s development and marketing efforts.

Critical Accounting Estimates and Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Note 1 to the Financial Statements describes the significant accounting policies and methods used in the preparation of the Financial Statements. Estimates are used for, but not limited to, contingencies and taxes. Actual results could differ materially from those estimates. The following critical accounting policies are impacted significantly by judgments, assumptions, and estimates used in the preparation of the Financial Statements.

We are subject to various loss contingencies arising in the ordinary course of business. We consider the likelihood of loss or impairment of an asset or the incurrence of a liability, as well as our ability to reasonably estimate the amount of loss in determining loss contingencies. An estimated loss contingency is accrued when management concludes that it is probable that an asset has been impaired, or a liability has been incurred and the amount of the loss can be reasonably estimated. We regularly evaluate current information available to us to determine whether such accruals should be adjusted.

We recognize deferred tax assets (future tax benefits) and liabilities for the expected future tax consequences of temporary differences between the book carrying amounts and the tax basis of assets and liabilities. The deferred tax assets and liabilities represent the expected future tax return consequences of those differences, which are expected to be either deductible or taxable when the assets and liabilities are recovered or settled. Future tax benefits have been fully offset by a 100% valuation allowance as management is unable to determine that it is more likely than not that this deferred tax asset will be realized.

Recent Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Off Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not applicable to smaller reporting companies.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to be effective in providing reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the “SEC”), and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure. Our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, they concluded that our disclosure controls and procedures were not effective for the quarterly period ended March 31, 2022.

The following aspects of the Company were noted as potential material weaknesses:

We do not have written documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act which is applicable to us for the period ended March 31, 2022, Management evaluated the impact of our failure to have written documentation of our internal controls and procedures on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

We do not as yet have sufficient resources in our accounting function, which restricts the Company’s ability to gather, analyze and properly review information related to financial reporting in a timely manner. In addition, due to our size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact of our failure to have segregation of duties on our assessment of our disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

We have inadequate controls to ensure that information necessary to properly record transactions is adequately communicated on a timely basis from non-financial personnel to those responsible for financial reporting. Management evaluated the impact of the lack of timely communication between non–financial personnel and financial personnel on our assessment of our reporting controls and procedures and has concluded that the control deficiency represented a material weakness.

Certain control procedures were unable to be verified due to performance not being sufficiently documented. As an example, some procedures requiring review of certain reports could not be verified due to there being no written documentation of such review. Management evaluated the impact of its failure to maintain proper documentation of the review process on its assessment of its reporting controls and procedures and has concluded deficiencies represented a material weakness.

In designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute assurance of achieving the desired objectives. Also, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs.

Changes in Internal Controls

Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that no changes occurred in the Company’s internal controls over financial reporting during the quarter ended March 31, 2022, that has materially affected, or is reasonably likely to materially affect, the Company’s internal controls over financial reporting.

PART II – OTHER INFORMATION

Item. 1. Legal Proceedings.

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

	1)	Wearable Health Solutions, In. v. Barry Honig, GRQ Consultants Inc., Benza Pharma LLC and John Does 1-10, Supreme Court of the State of New York County of New York, July 22, 2021. Company is disputing the validity of Notes from 3/2016 and seeking damages, reparations, and related costs.
	2)	GRQ Consultants, Inc. v. Wearable Health Solutions, Inc., Supreme Court of the State of New York, County of New York, August 26, 2021, Parties are seeking summary judgment of $50,000 plus accrued interest in response to lawsuit by Company regarding $50,000 loan from 11/2016.
	3)	Benza Pharma LLC, Sandor Capital, LP, and John Lema v. Wearable Health Solutions, Inc., District Court, Clark County, Nevada, Parties are seeking summary judgment of $3,000,000plus accrued interest in regards to convertible notes payable from March, 2016.

Medical Alarm Concepts LLC v. MCA Cure, LLC, Superior Court of New Jersey, Law Division, Morris County. Company is seeking return of payments for non-performance plus attorney fees and court costs. A settlement was reached between the parties whereby MCA Cure will pay an initial $10,000 and $6,500 each month until debt is satisfied in 2023 (See Note 14).

Item 1A. Risk Factors.

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, are not required to provide the information under this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Quarterly Issuances:

On January 6, 2022, Leonite Capital was issued a total of 20,000,000, common shares of the Company’s stock under the terms of the Regulation A offering which became qualified on November 12, 2020. The shares were issued under the terms of subscription agreements at the contracted price of $.01, in exchange for a total of $200,000, cash payments.

These securities were issued pursuant to Section 4(2) of the Securities Act, Rule 506 promulgated thereunder and Regulation A. The holders represented their intention to acquire the securities for investment only and not with a view towards distribution. The investors were given adequate information about us to make an informed investment decision. We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.

Subsequent Issuances:

Item 3. Defaults Upon Senior Securities.

None

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits

Exhibit Number		Exhibit Description
31.1		Certification of the Chief Executive Officer Pursuant to Rule 13a-14 or 15d-14 of the Exchange Act pursuant to Section 302 of the Sarbanes- Oxley Act of 2002
31.2		Certification of the Chief Financial Officer Pursuant to Rule 13a-14 or 15d-14 of the Exchange Act pursuant to Section 302 of the Sarbanes- Oxley Act of 2002
32.1		Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
EX-101.INS		Inline XBRL Instance Document the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document.
EX-101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
EX-101.SCH		Inline XBRL Taxonomy Extension Schema Document
EX-101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
EX-101.LAB		Inline XBRL Taxonomy Extension Labels Linkbase Document
EX-101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		The cover page from this Report, formatted in Inline XBRL (included in Exhibit 101)

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Wearable Health Solutions, Inc.

/s/ Harrysen Mittler		May 10, 2022
Harrysen Mittler, CEO, Principal Executive Officer, Director		Date

/s/ Gail Rosenthal		May 10, 2022
Gail Rosenthal, CFO, Principal Accounting Officer		Date

/s/ Peter Pizzino		May 10, 2022
Peter Pizzino, Director		Date